Current Mesothelioma Treatment and Future Perspectives by Štrbac, Danijela et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Current Mesothelioma Treatment 
and Future Perspectives
Danijela Štrbac, Katja Goričar, Viljem Kovač and Vita Dolžan
Abstract
The established treatments in malignant mesothelioma are based on trimodality 
approach including surgery, radiation and chemotherapy. Such approach has proved 
to clinically benefit mesothelioma patients, however the current treatments seem 
to have reached a limit regarding the survival and disease control. One approach to 
overcome the limitations of current treatments is focused on finding appropriate 
serum or genetic biomarkers that could support personalized medicine and improve 
outcomes with established treatment modalities in mesothelioma patients. The 
other approach is exploiting better understanding of molecular and genetic charac-
teristics of mesothelioma to search for new treatment modalities. Immunotherapy 
with anti PD-1, PD-L1 and CTLA-4 agents is a new frontier in mesothelioma 
treatment. As in many solid tumors, CAR-T cell therapy is emerging from the field 
of hematological malignancies. Immunomodulatory approaches seem to be a new 
perspective in treatment of malignant mesothelioma. This chapter aims to explore 
possible new therapeutic approaches in mesothelioma.
Keywords: mesothelioma treatment, genetic biomarkers, patient based therapy,  
gene therapy, immunomodulation
1. Introduction: trimodality approach to mesothelioma treatment
The established treatments in mesothelioma are based on trimodality approach 
including surgery, radiation and chemotherapy. Such concept for MM was intro-
duced in the late 1990s by Sugarbaker et al. It was proposed that the treatment of 
mesothelioma should start with extrapleural pneumonectomy (EPP) and followed 
by chemoradiation [1]. A study of 120 patients concluded that a 40% survival rate 
was feasible in patients with epithelial histology and negative nodes. A need for a 
more precise staging and more effective management strategies was stated [1].
Two and a half decades after the trimodality approach was introduced, 
little has changed in the treatment of mesothelioma. According to the National 
Comprehensive Cancer Network (NCCN) guidelines, in stages I to III of surgically 
operable mesothelioma, a chemotherapy regimen of pemetrexed with cisplatin or 
carboplatin is proposed in either preoperative or postoperative setting. For patients 
who received the entire trimodality approach, a median survival of 20 to 29 months 
has been reported [2, 3].
However, the majority of mesothelioma patients are diagnosed in advanced 
stages, are inoperable and/or have a poor performance (WHO performance status 
(PS) of 2 or above). Treatment with systemic chemotherapy significantly improves 
survival of MM patients and patients are usually treated with a platinum agent in 
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combination with either pemetrexed or gemcitabine [4, 5]. Studies have shown 
that both chemotherapy regimens have comparable results [4, 6, 7]. The only FDA 
approved treatment for advanced stages of mesothelioma is pemeterexed/cisplatin 
with possible options of vinorelbine or gemcitabine.
The combination with pemetrexed has become standard treatment in various 
clinical guidelines such as the NCCN, the European Society of Medical Oncology 
(ESMO) and American Society of Clinical Oncology (ASCO) [3, 8, 9]. In a 
Slovenian clinical study, gemcitabine in a prolonged infusion with cisplatin was 
shown as one of the most successful systemic treatments [4, 6]. Although current 
treatments clinically benefit mesothelioma patients, they seem to have reached a 
limit regarding the survival and disease control. One approach to overcome the 
limitations of current treatments is focused on finding appropriate serum or genetic 
biomarkers that could support personalized medicine and improve outcomes with 
established treatment modalities in mesothelioma patients [10].
A deeper understanding of tumor biology has also enabled the development 
of target drugs. These drugs target and inhibit the molecular signaling pathways 
along which a tumor develops, grows, and spreads. Several target drugs have been 
tested in the treatment of MM in the last few years, but so far no targeted treat-
ment has shown sufficient results to allow patients to be treated outside of clinical 
trials. Slovenian researchers also participated in one of these clinical trials with 
target drugs, focusing on bortezomib and cisplatin treatment [11]. The addition of 
bevacizumab to gemcitabine and cisplatin or pemetrexed and cisplatin has shown 
slightly better results. An addition of bevacizumab to the pemetrexed/cisplatin 
doublet has increased overall survival for up to 2.7 months, but it is suitable only for 
patients that do not have bleeding tendencies or a risk of thrombosis. Bevacizumab 
treatment has shown sufficiently promising results that it has come into routine use 
in the United States [12].
Among the novel treatment approaches, immunotherapy is becoming the most 
promising, especially with immune checkpoint inhibitors such as inhibitors of 
programmed cell death 1 (PD-1, PDCD1) and programmed cell death 1 ligand 1 
(PD-L1, CD274) [13]. Based on the results of clinical trials, it is currently estimated 
that 20–25% of patients with MM may benefit from treatment with immune 
checkpoint inhibitors [14].
Subsequent treatment lines are less effective in mesothelioma. Novel second line 
treatment approaches include immunotherapy with PD-1 inhibitors, such as pem-
brolizumab or nivolumab. Nivolumab can be used in a combination with CTLA-4 
inhibitor, ipilimumab [15, 16]. However, if immunotherapy is not accessible or has 
a high toxicity such as pneumonitis, a chemotherapy regimen with gemcitabine or 
vinorelbine is a valid option.
The aim of this chapter is to explore possible new therapeutic approaches in 
mesothelioma.
2.  Biomarker guided chemotherapy treatment in malignant 
mesothelioma
Research of biomarkers in malignant mesothelioma has been ongoing for the 
last twenty years. Predictive and prognostic biomarkers are also needed to support 
the treatment and follow up of patients with MM [17]. It has been shown that apart 
from clinical characteristics such as C-reactive protein or tumor stage, serum and 
genetic markers may be associated with treatment outcome in MM [10, 18–29]. 
Traditional research in mesothelioma biomarkers involves soluble molecules, such 
as mesothelin, fibulin and survivin [18, 20, 30], but novel serum biomarkers for 
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disease risk, diagnosis and treatment are also emerging [31]. Mesothelin is the only 
clinically validated biomarker in the diagnosis of mesothelioma. However, there are 
no predictive biomarkers that would allow patient stratification and a more person-
alized treatment approach. Studies have shown that patient stratification based on 
genetic biomarkers could improve chemotherapy outcome, but these approaches 
are not routinely used in the clinic yet [32, 33]. It is becoming more and more widely 
accepted that pharmacogenomics is enabling personalized medicine by testing for 
genetic variability in drug metabolizing enzymes, transporters, and drug targets 
thus accounting for interindividual variability in drug levels (pharmacokinetics), 
drug response (pharmacodynamics) and adverse events. Using pharmacogenomics 
approach, the treatment of malignant mesothelioma could perhaps be tailored also 
to individual’s genetic make-up, thereby promising safer and also more effective 
drug treatment [34–38].
2.1 Pharmacogenomics of cisplatin treatment
Cytotoxic activity of cisplatin and other platinum analogues is based on their 
ability to covalently bind to DNA, form intrastrand DNA adducts or interstrand 
cross-links, and lead to replication and transcription arrest. DNA adducts are 
recognized and repaired by nucleotide excision repair (NER) mechanisms. Genetic 
variability in NER genes such as ERCC excision repair 2 (ERCC2) and ERCC 
excision repair 1 (ERCC1) was associated with malignant mesothelioma treat-
ment outcomes [23, 39]. In particular, ERCC1 rs3212986 (c.*197G > T) wild-type 
genotype was significantly associated with better progression-free survival (PFS), 
but also with increased odds of treatment-related toxicities. The risk for cisplatin 
toxicity was also increased in patients with wild type genotype of ERCC2 rs1799793 
(p.Asn312Asp) polymorphism [23].
Interstrand crosslinks are among the most detrimental forms of DNA dam-
age because both DNA strands are affected. As translesion DNA polymerases are 
needed to bypass these crosslinks and restore one of the two DNA strands in order 
for repair mechanisms to proceed, they may also contribute to response to cisplatin 
treatment [40]. Studies have shown that disruption or suppression of expression of 
two genes participating in translesion repair, REV3L and REV1 modifies sensitivity 
to cisplatin [41, 42]. Similarly, REV3L polymorphisms rs465646 (c.*461C > T) and 
rs462779 (p. Thr1224Ile) were significantly associated with longer overall survival 
in MM patients treated with cisplatin based doublet chemotherapy, while REV1 
rs3087403 (p. Val138Met) allele and REV1 TGT haplotype were associated with 
increased risk for leukopenia and neutropenia [43].
2.2 Pharmacogenomics of pemetrexed treatment
Only a few studies investigated the influence of genetic polymorphism in the 
folate metabolic pathways on treatment outcome in MM patients that received 
antifolate chemotherapeutic pemetrexed [22, 44, 45]. MM patients with at least 
one polymorphic MTHFD1 rs2236225 (p.Arg653Gln) allele had a lower response 
rate and shorter PFS than carriers of two wild-type alleles. Furthermore, polymor-
phisms in pemetrexed transporter genes, such as ABCC2 and SLCO1B1 influenced 
the risk for toxicity in patients receiving antifolates [22]. Another study inves-
tigating 5,10-methylenetetrahydrofolate reductase (MTHFR) and ERCC1 gene 
polymorphisms failed to prove an association between the selected polymorphisms 
and treatment outcome, but did show that a 6-base pair insertion/deletion in the 3′ 
untranslated region of the thymidylate synthase TS gene was associated with differ-
ences in disease control rate and PFS in MM [44].
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2.3 Pharmacogenomics of gemcitabine treatment
Because gemcitabine is frequently used in combination with cisplatin in Slovenian 
mesothelioma patients, a study investigating pharmacogenomics factors that may 
influence the response to gemcitabine has also been performed. Deoxycytidine 
kinase and ribonucleotide reductase M1 (RRM1) were investigated as the main meta-
bolic and target enzymes, respectively. The study indicated that the RRM1 rs1042927 
(c.*316C > A) polymorphism significantly decreased overall survival. Two promoter 
polymorphisms, RRM1 rs11030918 (c.-524 T > C) and rs12806698 (c.-37C > A), 
decreased the odds of nausea and vomiting, while the RRM1 TTCCA haplotype was 
associated with worse tumor response and worse overall survival [25]. DNA repair 
gene polymorphisms, particularly XRCC1 rs25487 (p.Arg399Gln), may also modify 
the response to gemcitabine/platinum combination chemotherapy and effect overall 
survival in mesothelioma patients [24].
2.4  Clinical-pharmacogenomic models predicting outcome of malignant 
mesothelioma treatment
Pharmacogenomic findings motivated further research into developing a clinical-
pharmacogenomic model combining clinical and genetic data and an algorithm 
that would enable treatment stratification in MM. The clinical-pharmacogenomic 
model that could help predict response to gemcitabine/cisplatin combination and 
survival of MM patients included C-reactive protein, histological type, performance 
status, RRM1 rs1042927, ERCC2 rs13181, ERCC1 rs3212986, and XRCC1 rs25487. The 
clinical-pharmacogenomic model that could help predict response to pemetrexed/
cisplatin combination included C-reactive protein, MTHFD1 rs2236225, and ABCC2 
rs2273697 [10]. An algorithm for treatment stratification was proposed based on 
both clinical-pharmacogenomic models, where a more favorable chemotherapy 
regimen could be recommended in 64.2% of patients: pemetrexed/cisplatin in 
35.9% and gemcitabine/cisplatin in 28.3%. The algorithm predicted that 21.4% 
of patients would respond equally well to both treatments, but 14.5% of patients 
would probably not respond well to either [10]. The algorithm requires further 
independent validation, before it could be used in the clinical decision making, but 
is nevertheless proof that a tailored treatment could be applied in mesothelioma 
chemotherapy.
3. Future perspectives in the treatment of mesothelioma
3.1 Immunotherapy in mesothelioma
Immunotherapeutic approach is proposed as second line treatment in 
mesothelioma. It entails three basic immunological targets as either anti-PD-1 
(nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab) or anti-
CTLA-4 (ipilimumab) or in combination, such as nivolumab/ipilimumab. The 
most promising trial data come from a combination of ipilimumab and nivolumab 
with median survival of 15.9 months. However, there is 94% rate of treatment 
related adverse events with combination immunotherapy [15].
Therefore, monotherapy approaches have been proposed in second line setting. 
Pembrolizumab in monotherapy is promising with a 20% partial response rate 
with a median response duration of one year. Grade 3 or 4 toxicity rate is reported 
at 20% [46, 47].
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These data, however promising, present a high rate of toxicity and rather limited 
response and survival rates. With analogy to the genetic biomarkers for cytotoxic 
chemotherapy, further research should be done to determine genetic biomarkers in 
immunotherapy [48].
3.2 Gene therapy in mesothelioma
The principle of gene therapy is to infiltrate tumor cells and deactivate genes 
involved in tumor growth and progression. Classical example of gene therapy is to 
target p53 expression and induce apoptosis in mesothelioma cells. Several clinical 
trials targeted crucial pathways in mesothelioma cells that would ultimately lead to 
cell death using oncolytic viruses as vectors. The genes injected in these trials were 
interleukin-2, interferon α2b, herpes simplex virus thymidine kinase, and interferon 
β. The response was achieved mostly around the injected site in the pleural cavity, 
however some clinical response was noted months after injection into tumor site. 
The direct cell death that was the goal of this gene therapy was limited, however 
a delayed immune response was proposed since several antibodies were found in 
patients with response to treatment [49].
While gene therapy with oncolytic viruses as vectors of injection has been tested 
as monotherapy, combination with chemotherapy has been proposed to achieve a 
dual effect of local and systemic disease control [50–53].
3.3 CAR-T cells in mesothelioma
Chimeric antigen receptors (CARs) are genetically encoded artificial fusion 
molecules that can re-program the specificity of peripheral blood polyclonal T-cells 
against a selected cell surface target. The overall structure of a CAR consists of 
four domains joined in series, namely: an antigen recognition domain (targeting 
moiety), a hinge/spacer, a transmembrane element and a signaling endodomain. 
The CAR ectodomain determines target specificity and, most commonly, contains 
elements derived from a monoclonal antibody [54].
Unparalleled clinical efficacy has recently been demonstrated using this approach 
to treat patients with refractory B-cell malignancy, such as lymphomas. Solid tumors 
were the next to be included in CAR T cell (CAR-T) immunotherapy, but have posed 
certain toxicity challenges, such as on target off tumor toxicity. A fatal toxicity was 
noted in human epidermal growth factor receptor 2 (HER-2) CAR-T cells which led 
to respiratory and multi organ failure with cytokine release syndrome [55].
Also mesothelioma has been studied in the setting of CAR-T therapy. An in vitro 
study of MET receptor tyrosine kinase specific CAR-T cells was designed to target 
MET expressing mesothelioma cells. The data from the in vivo animal models showed 
that this type of CAR therapy can be safe and effective in MET expressing mesothe-
lioma [56]. A small study reported two patients treated with mesothelin targeting 
CAR-T cells (CAR-T meso cells). The investigators in this study used a novel approach 
of mRNA engineered CAR-T cells to overcome the off- tumor on target toxicity. They 
concluded that the treatment with CAR-T meso cells is feasible in pretreated patients 
with progressive disease, since they reported partial tumor response [57].
4. Conclusions
The treatment of mesothelioma presents a clinical challenge, especially in the 
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current treatment strategies, in particular the response to chemotherapy, by enabling 
pharmacogenomics based informed selection of patients who would benefit most 
from a particular treatment regimen. Based on our previous studies, clinical-
pharmacogenomic prediction models and algorithms could facilitate treatment 
stratification and contribute to improved treatment outcome in MM. The future 
of mesothelioma treatment seems to involve immunologically based treatment 
with either the already present immunotherapy or the evolving CAR-T therapy. 
The innovation of the decades old principles of CAR-T cell therapy has proven to 
be successful in hematological malignancies and mesothelioma seems to be on the 
forefront of research in solid tumors with such innovations as are the mRNA CAR-T 
meso cells.
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